Humanity’s List

Section

Medicine

Trials, therapies, and evidence that changes care.

Daily at 06:15 UTC

Edition No. 30
Updated UTC

Stronger verdicts first · Score orders stories within each verdict

Europe PMC

Verdict: Major

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China

Izalontamab brengitecan (iza-bren) is a first-in-class bispecific antibody-drug conjugate targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) and has shown…

By Hong, Zhou, Hou +43Lancet (London, England)

Score█████░░░░░5.5

Top stories

  1. 1. Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial

    Trastuzumab rezetecan (SHR-A1811) has demonstrated encouraging antitumor activity in a global phase 1 trial involving heavily pretreated patients with erythroblastic oncogene B (ERBB2)-low metastatic breast…

    Verdict: Major█████░░░░░5.5

  2. 2. Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial

    Patients with heavily pretreated hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer have few treatment options.

    Verdict: Major█████░░░░░5.4

More top stories

No.03 to No.06

  1. Europe PMCby Wang, Li, Xu +39

    Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer

    The combination of docetaxel, trastuzumab, and pertuzumab (THP) is an established first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer.

    No.03Verdict: MajorScore█████░░░░░5.3
  4. Europe PMCby Xu, Zhang, Lin +35

    Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China

    Ruzaltatug rezetecan is a novel HER3-directed antibody-drug conjugate that has shown promising antitumour activity and manageable safety in pretreated EGFR-.mutated non-small-cell lung ....

    No.06Verdict: MajorScore█████░░░░░5.3

Briefs

8 more from the desk